Compare · AVIR vs NVO
AVIR vs NVO
Side-by-side comparison of Atea Pharmaceuticals Inc. (AVIR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVIR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 556.6x AVIR ($336.9M).
- Over the past year, AVIR is up 30.4% and NVO is down 41.7% - AVIR leads by 72.1 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 7 for AVIR).
- NVO has more recent analyst coverage (25 ratings vs 13 for AVIR).
- Company
- Atea Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $4.20-1.87%
- $42.01-2.10%
- Market cap
- $336.9M
- $187.53B
- 1M return
- -26.32%
- -5.38%
- 1Y return
- +30.43%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 7
- 11
- Recent ratings
- 13
- 25
Atea Pharmaceuticals Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AVIR
- Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
- Amendment: Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)
- Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)
- Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
- SEC Form 10-Q filed by Atea Pharmaceuticals Inc.
- Atea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.
- Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
- SEC Form DEFA14A filed by Atea Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates